X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/28/2888943/0/en/HiberCell-Announces-First-Patient-Dosed-in-Phase-1b-Clinical-Trial-Evaluating-HC-7366-in-Combination-with-Venetoclax-and-Azacitidine-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML.html
https://www.globenewswire.com/news-release/2024/05/01/2873708/0/en/HiberCell-Announces-First-Patient-Dosed-in-Clinical-Collaboration-with-Merck-Evaluating-HC-7366-in-Combination-with-WELIREG-belzutifan-in-patients-with-advanced-ccRCC.html
https://www.globenewswire.com/news-release/2024/04/05/2858583/0/en/HiberCell-Announces-Recent-Publication-and-Poster-Presentations-for-its-Novel-GCN2-Activator-HC-7366.html
https://www.globenewswire.com//news-release/2023/12/15/2797135/0/en/HiberCell-Announces-Presentation-at-ASH-Highlighting-Preclinical-Data-for-HC-7366-with-Standard-of-Care-Agents-in-Acute-Myeloid-Leukemia-AML.html
https://www.globenewswire.com/news-release/2023/12/05/2791096/0/en/HiberCell-Inc-Announces-Clinical-Collaboration-with-Merck-to-Evaluate-HC-7366-an-Activator-of-ISR-Kinase-GCN2-in-Combination-with-WELIREG-belzutifan-in-a-Phase-1b-Study-of-Patients.html
https://www.globenewswire.com//news-release/2023/11/27/2786292/0/en/HiberCell-Announces-Successful-Completion-and-Interim-Results-of-Phase-1-Study-of-Novel-PERK-Inhibitor-HC-5404-in-Solid-Tumors-and-Maps-Forward-Path-as-Monotherapy-and-in-Combinati.html
https://www.globenewswire.com/news-release/2023/05/22/2673773/0/en/HiberCell-Doses-First-Patient-in-Phase-1b-Study-Exploring-Novel-Combination-of-Odetiglucan-and-CD40-Agonistic-Monoclonal-Antibody-CDX-1140-in-Patients-With-Metastatic-Pancreatic-Du.html
https://www.globenewswire.com/news-release/2023/03/24/2633877/0/en/HiberCell-to-Present-Pre-clinical-Data-on-its-Novel-GCN2-Activator-and-PERK-Inhibitor-Programs-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2023.html
https://www.globenewswire.com/news-release/2023/02/22/2613169/0/en/HiberCell-Maps-Forward-Path-for-Novel-GCN2-Activator-HC-7366-in-Acute-Myeloid-Leukemia-AML.html
https://www.globenewswire.com/news-release/2022/11/02/2546997/0/en/HiberCell-to-Present-Preclinical-Data-from-Novel-GCN2-Activator-and-PERK-Inhibitor-Programs-at-The-Society-for-Immunotherapy-of-Cancer-SITC-37th-Annual-Meeting.html
Market Place
Share 
